X

Dispensing with the Truth: The Victims, the Drug Companies, and the Dramatic Story Behind the Battle over Fen-Phen

Product ID : 18989467


Galleon Product ID 18989467
Model
Manufacturer
Shipping Dimension Unknown Dimensions
I think this is wrong?
-
Restricted product. We cannot ship these kind of products

Pay with

About Dispensing With The Truth: The Victims, The Drug

Product Description Semi-finalist for the Robert F. Kennedy Memorial Book Award In 1996, a terrible epidemic began killing young American women. Some died quickly, literally dropping in their steps. Others took more time, from a few months to a few years. Those who weren't killed suffered damage to their lungs and hearts, much of it permanent and reparable only with major surgery. Doctors suspected what the killer was. So did the Food and Drug Administration. The culprits were the two most popular diet drugs in the United States, Pondimin, one-half of the popular drug combination Fen-Phen, and Redux, a stronger version of Pondimin. They were also two of the most profitable drugs on the market, and both were produced and sold by a powerful pharmaceutical company, Wyeth-Ayerst, a division of American Home Products. Dispensing the Truth is the gripping storry of what the drug really knew about its drugs, the ways it kept this information from the public, doctors, and FDA, and the massive legal battles that ensued as victims and their attorneys searched for the truth behind the debacle. It tells the story of a healthy young woman, Mary Linnen, who took the drugs for only twenty-three days to lose weight before her wedding, and then died in the arms of her fiance a few months later. Hers was the first wrongful-death suit filed amd would become the most important single suit the company would ever face. Alicia Mundy provides a shocking and thoroughly riveting narrative. It is a stark look at the consequences of greed and a cautionary tale for the future. Amazon.com Review Mary Linnen, 29, was determined to lose 25 pounds before her wedding. In May 1996, her doctor prescribed a combination of drugs known as Fen-Phen. When Linnen complained of dizziness and shortness of breath 23 days after starting the medications, her doctor told her to stop the drugs--but didn't examine her or order tests. Linnen got better for a time, then the shortness of breath and exhaustion returned worse than ever. Her legs and stomach swelled. She collapsed at work. Six months after taking Fen-Phen, Linnen was admitted to the emergency room with primary pulmonary hypertension: the capillaries that sent oxygen to her lungs had thickened and were closing, suffocating her. Her survival expectation after heart surgery was less than four years. Hooked up to a tube in her chest to prevent heart failure, she died three months later. Dispensing with the Truth: The Battle over Fen-Phen tells the story of the legal battle against the pharmaceutical companies after Fen-Phen's users started dying--some, like Linnen, of primary pulmonary hypertension; others of heart valve damage. Investigative reporter Alicia Mundy weaves a dramatic tale from the development of the drugs to FDA approval to the final litigation. How much did the pharmaceutical companies know about the risks long before most of the deaths? Plenty, according to the evidence Mundy reveals. Although at times the book seems overfilled with details that slow down the drama, if you want the complete, behind-the-scenes story of one of the most famous "profits over protection" cases, this book tells all. --Joan Price From Publishers Weekly H"You are going to hear about a diet pill combination that was a craze... one of the most remarkably profitable pharmaceutical undertakings in the history of the United States," said Alex MacDonald, as quoted here by Mundy, in his opening statement during the Mary Linnen case. Beginning with the death of Linnen, a young woman who took Fen-Phen for less than a month to lose a few pounds before her wedding and died of primary pulmonary hypertension less than a year later, Mundy's book reads like a medical thriller. But the story of the lives affected by the flawed obesity drug is all too true: approximately 45,000 women "were believed to have developed one of two different diseases linked to their lungs or their heart from taking the drugs"; 300,000 women were